CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 156 enrolled
Drug / intervention
Praziquantel +3 moredrug
Likely dose
Praziquantel 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00441285
NCT00441285Phase 3Completed
CompareCT.gov

Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole

Universidad Peruana Cayetano Heredia·interventional·Posted Feb 28, 2007·Updated Jun 11, 2015

In Brief

A Phase 3 clinical trial evaluating Praziquantel, Albendazole, and 2 other interventions for Neurocysticercosis and Epilepsy. Completed, enrolled 156 participants across 5 sites.

Detailed Summary

The purpose of this study is to determine if combination drug therapy of praziquantel and albendazole is safe and effective to cure neurocysticercosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurocysticercosis, Epilepsy
CountriesPeru
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 28, 2007
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 19.3 years ago

Interventions

Praziquanteldrug

\- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.

Albendazoledrug

* Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days. * Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.

ABZ Placebodrug

\- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.

PZQ Placebodrug

\- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.